When Abbott signed its multi-year siRNA drug-discovery collaboration with Dharmacon, it marked the culmination of a one-and-a-half year effort to evaluate RNAi as a therapeutic modality, according to an official from the healthcare giant.
And now that it has officially jumped into the RNAi-based therapeutics pool, Abbott may start signing more partnerships in the field.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
